4.6 Article

The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond

期刊

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/jnnp-2013-304943

关键词

-

资金

  1. Medtronic
  2. Merz Pharmaceuticals
  3. Acadia
  4. Siena
  5. Neurosearch Sweden
  6. Phytopharm
  7. Schering-Plough
  8. Avid Radiopharmaceutical
  9. Allergan, Inc
  10. Allon Therapeutics
  11. Biotie
  12. Ceregene, Inc
  13. Chelsea Therapeutics
  14. Diana Helis Henry Medical Research Foundation
  15. EMD Serono
  16. Huntington's Disease Society of America
  17. Huntington Study Group
  18. Impax Pharmaceuticals
  19. Ipsen Limited
  20. Lundbeck Inc
  21. Michael J Fox Foundation for Parkinson Research
  22. National Institutes of Health
  23. National Parkinson Foundation
  24. Neurogen
  25. St. Jude Medical
  26. Teva Pharmaceutical Industries Ltd
  27. University of Rochester
  28. Parkinson Study Group

向作者/读者索取更多资源

Background Deep brain stimulation (DBS) has proven to be a safe and effective therapy for refractory essential tremor, but information regarding long-term outcomes is lacking. Objectives We aimed to assess the long-term safety and efficacy of DBS in patients with essential tremor. Methods Patients treated with DBS for essential tremor for at least 8 years were evaluated in the 'on' and 'off' state using the Fahn-Tolosa-Marin tremor rating scale, and their medical records were reviewed to assess complications related to this therapy. Results We studied 13 patients (7 men): median age at evaluation 79 years (range 47-88), median age at electrode implantation 68 years (range 37-78) and mean time since electrode implantation 132.54 +/-15.3 months (range 114-164). The difference between the 'off' and 'on' state on the motor items of the tremor rating scale was 41.9% (58.62 vs 34.08, p<0.001) in the non-blinded and 37.2% (56.07 vs 35.23, p<0.001) in the blinded rating. DBS provided a functional improvement of 31.7% in the 'on' state (15.07 vs 22.07, p<0.001). A total non-blinded improvement in the tremor rating scale of 39% was observed in the 'on' state (49.15 vs 80.69, p<0.001). Dysarthria and disequilibrium were common in patients with bilateral stimulation. A DBS-related surgery (electrode revision or internal pulse generator exchange) was necessary on average every 47.9 months to continue with the DBS therapy. Conclusions Thalamic DBS is a safe and effective therapy in patients with essential tremor followed for up to 13 years.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据